However, the treatment modulated the KRAS downstream signaling pathway, with significantly decreased staining for phosphorylated ERK1/2, but not phosphorylated AKT, detected for both AF and ER treatments (Fig. 4D-F). This evidence concerns the gene MAPK3 and atrial fibrillation.